Printer Friendly

Higher Dose of Mesalamine is More Effective in Moderately Active Ulcerative Colitis.

CHICAGO, May 17 /PRNewswire/ -- Two recent studies have found that for patients with moderately active ulcerative colitis, beginning treatment with twice the standard dose of mesalamine -- 4.8 grams per day rather than 2.4 grams - was more effective with no increase in side effects.

The consistent findings could change the way patients with moderately active ulcerative colitis are treated, said lead investigator Stephen Hanauer, M.D., professor of medicine and clinical pharmacology and section chief of gastroenterology and nutrition at the University of Chicago Pritzker School of Medicine. Hanauer presented results from the trials, known as ASCEND I and II, at the Digestive Disease Week(R) 2005 annual scientific meeting in Chicago.

"Moderately active ulcerative colitis is a distinct disease classification that warrants aggressive treatment," Hanauer said. "Most patients suffer from moderately active disease, but very few receive 4.8 grams per day. Some are switched from standard dose mesalamine to other therapies before they are offered a higher dose."

Simon Travis, M.D., consultant gastroenterologist at the John Radcliffe Hospital, Oxford, commented, "In one of the largest trials of 5-ASA in acute colitis, 4.8g of Asacol per day was well tolerated and demonstrated an encouraging response."

"This represents two useful advances," added John Rhodes, M.D., professor of medicine at the University of Liverpool. "The 800mg tablet that should considerably increase ease of use for long-term maintenance and the demonstration that high dose (4.8 g/day) Asacol should prove better for moderately active ulcerative colitis than the lower doses that we have been using up till now."

The ASCEND (Assessing the Safety and Clinical Efficacy of a New Dose of 5-ASA) I and II studies -- sponsored by Procter & Gamble, which makes both drugs -- were randomized, controlled, phase-III clinical trials designed to compare 4.8 grams per day with an 800 mg tablet of mesalamine to 2.4 grams per day with a 400 mg tablet for six weeks. A total of 687 patients were randomized in ASCEND I and II, of which 423 analyzable patients (169 in ASCEND I, 254 in ASCEND II) had moderately active UC.

Measures of success were clinical, endoscopic, and physicians' global assessments. In these studies 72 percent of patients taking 4.8 grams a day of mesalamine achieved success compared to 58 percent of patients taking 2.4 grams of mesalamine, (p<0.05). Overall adverse events were similar in both treatment groups. The most common side effects (headache, gastrointestinal symptoms including abdominal pain, diarrhea, nausea, vomiting, flatulence, dyspepsia and respiratory symptoms consistent with respiratory infections or flu syndrome) were similar to those seen in previous lower-dose studies.

"Patients may take as many as twelve 400 milligram tablets a day to manage symptoms of the disease, including bleeding and cramping," Hanauer said. "The 800 milligram tablet allows patients with moderate ulcerative colitis to receive 4.8 grams per day of mesalamine by taking six tablets a day."

Mesalamine was approved in 1992 at a dose of 2.4 grams per day for the treatment of mild to moderate ulcerative colitis. The most frequent adverse events reported for treatment at that level versus placebo, were headache (35% vs. 36%), abdominal pain (18% vs. 14%), and eructation (16% vs. 15%).

Patients who are hypersensitive to salicylates, such as aspirin, should not take mesalamine. Caution should be exercised when using mesalamine in patients with kidney disease. All patients should have an evaluation of renal function prior to beginning treatment and periodically while on therapy. As with other mesalamine-containing products, serious adverse events may occur.

About Ulcerative Colitis

Ulcerative colitis involves inflammation of the lining of the colon and rectum. It varies in clinical severity with patients having mild, moderate or severe disease. Treatment dependds on the severity of disease

It causes flares followed by periods of remission. During a flare, in which the rectum or colon become inflamed, people experience symptoms such as diarrhea, rectal bleeding, abdominal cramping and an urgent need to go to the bathroom. Flares can vary in duration and intensity.

While ulcerative colitis is a lifelong condition, flares can be controlled with medication.

Ulcerative colitis affects people of all ages, but often is diagnosed during early adulthood. The causes of this condition are unknown, but may involve heredity, infection or the immune system.

About Digestive Disease Week

Digestive Disease Week (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 14-19, 2005 in Chicago. The meeting showcases approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology.

John Easton of The University of Chicago Hospitals, +1-773-702-6241, john.easton@uchospitals.edu
COPYRIGHT 2005 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire Europe
Date:May 17, 2005
Words:818
Previous Article:Michelob ULTRA Goes for Gold.
Next Article:US$500,000 John Templeton Foundation Grant Awarded to Mercatus Center at George Mason University.


Related Articles
Study Demonstrates New Treatment Option for Patients With Moderately Active Ulcerative Colitis.
Revised Information: Study Demonstrates New Treatment Option for Patients with Moderately Active Ulcerative Colitis.
Double-dose Asacol improves outcomes in ulcerative colitis.
Higher Dose of Mesalamine Is More Effective in Moderately Active Ulcerative Colitis.
SPD476 Phase II Study Results Presented at World Congress of Gastroenterology.
Asacol Induced Rapid Mucosal Healing in Ulcerative Colitis Patients.
Analysis Shows Treatment Response to Mesalamine Associated With Rapid Mucosal Healing in Patients With Moderately Active Ulcerative Colitis.
New Study Shows Adherence to Ulcerative Colitis Medications Is Not Affected by Drug Formulation or Dosing Regimen.
FDA Approves LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine for Patients With Active, Mild to Moderate Ulcerative Colitis.
MultiVu Video Feed: U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVES LIALDA(TM) (mesalamine).

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters